NCT05440799View on ClinicalTrials.gov

A Study to Test How Healthy Women Tolerate Different Doses of BI 1819479

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

July 20, 2022

Primary Completion Date

August 2, 2023

Study Completion Date

August 2, 2023

Conditions
Healthy
Interventions
DRUG

BI 1819479

BI 1819479

DRUG

BI matching placebo

BI matching placebo

Trial Locations (1)

68167

CRS Clinical Research Services Mannheim GmbH, Mannheim

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05440799 - A Study to Test How Healthy Women Tolerate Different Doses of BI 1819479 | Biotech Hunter | Biotech Hunter